Survodutide vs Tirzepatide

Survodutide wins for visceral and hepatic fat reduction, thermogenic effects, and rapid improvement in NAFLD/MASH protocols. More aggressive body recomposition, especially in lifters managing liver health or severe visceral fat, and a mechanistically richer cutting tool when side-effect management is squared away.

Tirzepatide wins for appetite suppression, glycemic control, and overall tolerability. The GI side effect profile is milder, titration is more forgiving, and sourcing is simpler. For sustainable appetite governance, especially in lean bulks or long contest prep, tirzepatide remains the easier protocol to maintain.

Pick Survodutide if:

• Rapid visceral and hepatic fat loss is the primary goal (e.g., aggressive NAFLD reversal or post-orals liver cleanup)
• A more thermogenic, "warmer" feel is desired during a cut
• GLP-1 agonists alone have plateaued for further fat loss
• Willing to tolerate a longer, more challenging titration for mechanistic advantages
• Cutting-edge protocols for serious body recomp or advanced contest prep are being designed

Pick Tirzepatide if:

• Appetite suppression and glycemic control are the main objectives (e.g., bridging between cuts, microdosing for bulk appetite control)
• A smoother titration and fewer GI side effects are a priority
• Lean mass retention is managed actively (test base, high protein, heavy resistance), with an easier overall experience
• Simpler sourcing or cost control is needed
• Long-term sustainability and compliance take precedence over marginal increases in fat loss